Optimind Pharma Corp.

As of February 28, 2026, Optimind Pharma Corp. has 103.15M shares outstanding.

These figures are as of February 28, 2026. The EV/Sales ratio of 0.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Optimind Pharma Corp. trades at an EV/FCF ratio of 1.36, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of February 28, 2026, Optimind Pharma Corp. maintains a current ratio of 0.43, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended February 28, 2026. Return on assets (ROA) is negative at -66.36, reflecting losses generated across the asset base.

Over the twelve months ended February 28, 2026, Optimind Pharma Corp. posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -56.01 and net profit margin of -97.23 provide insight into operational efficiency.

These figures cover the twelve months ended February 28, 2026. Total shareholder yield is negative at -52.35, meaning Optimind Pharma Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of February 28, 2026, Optimind Pharma Corp. has an Altman Z-Score of -52.94, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.